Kyntra Bio, Inc. KYNB 深 滬
等待開盤 06-11 09:30:00 美东时间
6.69
0.000
0.00%
華盛通- 最 高6.991
- 今 開6.83
- 成交量 1.13万股
- 最 低 6.61
- 昨 收 6.69
- 總市值 2708.19万
- 52周最高 12.60
- 市盈率 靜 0.15
- 換手率 0.00%
- 52周最低 4.85
- 委 比 -99.00%
- 總股本 404.81万
- 歷史最高 1713.75
- 量 比 1.16
- 振 幅 5.70%
- 歷史最低 4.50
- 每 手 1
- 風險率 1.86%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅321.55%！Shattuck Labs获花旗升目标价至18美元，维持"买入"评级
今日重点评级关注：花旗：维持Shattuck Labs"买入"评级，目标价从7美元升至18美元；Benchmark：维持Gloo Holdings"买入"评级，目标价从14美元升至15美元
06-10 12:32
Rodman & Renshaw Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $30
Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Buy rating and announces Price Target of $30.
06-09 19:50
Kyntra Bio Q1 EPS $(3.76) Down From $1.15 YoY, Sales $3.738M Up From $2.739M YoY
Kyntra Bio (NASDAQ:KYNB) reported quarterly losses of $(3.76) per share. This is a 426.96 percent decrease over earnings of $1.15 per share from the same period last year. The company reported $3.738 million in sales
05-12 04:09
Earnings Scheduled For May 11, 2026
Companies Reporting Before The Bell • United Parks & Resorts (NYSE:PRKS) is...
05-11 19:11
电话会总结 ｜ Kyntra Bio(KYNB)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Kyntra Bio业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 2025年第四季度营收130万美元，全年营收640万美元 - 2024年第四季度营收310万美元，全年营收2,960万美元 **亏损情况：** - 2025年第四季度持续经营业务净亏损1,460万美元（每股亏损3.61美元） - 2025年全年持续经营业务净亏损5,820万美元（每股亏损14.40美元） - 2024年第四季度持续经营业务净亏损870万美元（每股亏损2.15美元） - 2024年全年持续经营业务净亏损15,310万美元（每
03-17 12:09
Kyntra Bio Q4 EPS $(3.61) Beats $(3.71) Estimate, Sales $1.300M Miss $1.425M Estimate
Kyntra Bio (NASDAQ:KYNB) reported quarterly losses of $(3.61) per share which beat the analyst consensus estimate of $(3.71) by 2.56 percent. This is a 80.5 percent decrease over losses of $(2.00) per share from the same
03-17 04:03
Earnings Scheduled For March 16, 2026
Companies Reporting Before The Bell • CytomX Therapeutics (NASDAQ:CTMX) is expe...
03-16 19:11
What's Going On With Kyntra Bio Stock Tuesday?
Kyntra Bio announces positive data for FG-3246 plus enzalutamide in metastatic castration-resistant prostate cancer.
02-24 21:27
